Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMR1CLY)

Drug Name

GC376 Drug Info

Synonyms

CS-6923; HY-100721; CHEMBL2315036

Indication

Disease Entry	ICD 11	Status	REF
Middle East Respiratory Syndrome (MERS)	1D64	Preclinical	[1]
Severe acute respiratory syndrome (SARS)	1D65	Preclinical	[1]
Coronavirus Disease 2019 (COVID-19)	1D6Y	Investigative	[2]

Therapeutic Class

Antiviral Agents

Cross-matching ID

PubChem CID: 71481119
CAS Number: CAS 1416992-39-6
TTD Drug ID: DMR1CLY

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Approved Drug(s)

Clinical Trial Drug(s)

Preclinical Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting COVID-19 3C-like protease (3CLpro)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
BOCEPREVIR	DMBSHMF	Hepatitis C virus infection	1E51.1	Approved	[2]
PF-07817883	DMNX86H	Coronavirus Disease 2019 (COVID-19)	1D6Y	Phase 1	[3]
GRL001	DM19T2V	Coronavirus infection	1D92	Preclinical	[4]
------------------------------------------------------------------------------------

Drug(s) Targeting MERS-CoV 3C-like proteinase (3CLpro)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Lopinavir	DMITQS0	Human immunodeficiency virus infection	1C62	Approved	[4]
PMID26868298-compound-N3	DMQFUCD	Middle East Respiratory Syndrome (MERS)	1D64	Preclinical	[4]
PMID28216367-compound-6d	DMPWUFT	Middle East Respiratory Syndrome (MERS)	1D64	Preclinical	[5]
PMID27240464-compound-3f	DMPC29W	Middle East Respiratory Syndrome (MERS)	1D64	Preclinical	[6]
GRL-001	DMVB1PD	Middle East Respiratory Syndrome (MERS)	1D64	Preclinical	[4]
GC813	DM7PBJC	Middle East Respiratory Syndrome (MERS)	1D64	Preclinical	[7]
------------------------------------------------------------------------------------


⏷ Show the Full List of 6 Drug(s)

Drug(s) Targeting SARS-CoV 3C-like protease (3CLpro)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Lopinavir	DMITQS0	Human immunodeficiency virus infection	1C62	Approved	[4]
PMID26868298-compound-N3	DMQFUCD	Middle East Respiratory Syndrome (MERS)	1D64	Preclinical	[4]
PMID28216367-compound-6d	DMPWUFT	Middle East Respiratory Syndrome (MERS)	1D64	Preclinical	[5]
PMID27240464-compound-3f	DMPC29W	Middle East Respiratory Syndrome (MERS)	1D64	Preclinical	[6]
GRL-001	DMVB1PD	Middle East Respiratory Syndrome (MERS)	1D64	Preclinical	[4]
Phenylisoserine derivatives SK80	DM16W8F	Severe acute respiratory syndrome (SARS)	1D65	Preclinical	[8]
PMID30784880-compound-6-5	DMVB0P3	Severe acute respiratory syndrome (SARS)	1D65	Preclinical	[9]
PMID28624700-compound-3-31	DMYNCWK	Severe acute respiratory syndrome (SARS)	1D65	Preclinical	[10]
------------------------------------------------------------------------------------


⏷ Show the Full List of 8 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
COVID-19 3C-like protease (3CLpro)	TT1D53B	R1AB_SARS2 (3264-3569)	Inhibitor	[2]
MERS-CoV 3C-like proteinase (3CLpro)	TTWOH4Q	R1AB_CVEMC (3248-3553)	Inhibitor	[1]
SARS-CoV 3C-like protease (3CLpro)	TTPZG3C	R1AB_CVHSA (3241-3546)	Inhibitor	[1]

------------------------------------------------------------------------------------

References

1	Reversal of the Progression of Fatal Coronavirus Infection in Cats by a Broad-Spectrum Coronavirus Protease Inhibitor. PLoS Pathog. 2016 Mar 30;12(3):e1005531.
2	Boceprevir, GC-376, and calpain inhibitors II, XII inhibit SARS-CoV-2 viral replication by targeting the viral main protease. 2020. April 20. doi: https://doi.org/10.1101/2020.04.20.051581
3	ClinicalTrials.gov (NCT05580003) COVID-19: A MULTIPART, PHASE 1 STUDY WITH RANDOMIZED, DOUBLE-BLIND, SPONSOR-OPEN, PLACEBO-CONTROLLED, SINGLE- AND MULTIPLE-DOSE ESCALATION TO EVALUATE THE SAFETY, TOLERABILITY AND PHARMACOKINETICS OF PF-07817883 AND OPTIONAL OPEN-LABEL, RANDOMIZED STUDY TO EVALUATE RELATIVE BIOAVAILABILITY AND FOOD EFFECT OF SOLID ORAL FORMULATION AND OPTIONAL OPEN-LABEL, NON-RANDOMIZED STUDY TO EVALUATE METABOLISM AND EXCRETION OF PF-07817883 AND OPTIONAL RANDOMIZED, OPEN-LABEL STUDY TO ASSESS THE EFFECT OF PF-07817883 ON PHARMACOKINETICS OF MIDAZOLAM IN HEALTHY ADULT PARTICIPANTS. U.S.National Institutes of Health.
4	Coronaviruses - drug discovery and therapeutic options. Nat Rev Drug Discov. 2016 May;15(5):327-47.
5	Identification and evaluation of potent Middle East respiratory syndrome coronavirus (MERS-CoV) 3CLPro inhibitors. Antiviral Res. 2017 May;141:101-106.
6	Identification, synthesis and evaluation of SARS-CoV and MERS-CoV 3C-like protease inhibitors. Bioorg Med Chem. 2016 Jul 1;24(13):3035-3042.
7	Structure-guided Design of Potent and Permeable Inhibitors of MERS Coronavirus 3CL Protease That Utilize a Piperidine Moiety as a Novel Design Element Eur J Med Chem. 2018 Apr 25;150:334-346.
8	Synthesis and Evaluation of Phenylisoserine Derivatives for the SARS-CoV 3CL Protease Inhibitor. Bioorg Med Chem Lett. 2017 Jun 15;27(12):2746-2751.
9	Chemical synthesis, crystal structure, versatile evaluation of their biological activities and molecular simulations of novel pyrithiobac derivatives. Eur J Med Chem. 2019 Apr 1;167:472-484.
10	Discovery of Unsymmetrical Aromatic Disulfides as Novel Inhibitors of SARS-CoV Main Protease: Chemical Synthesis, Biological Evaluation, Molecular Docking and 3D-QSAR Study Eur J Med Chem. 2017 Sep 8;137:450-461.